Counter-regulatory effects played by the ACE - Ang II - AT1 and ACE2 - Ang-(1 - 7) - Mas axes on the reactive oxygen species-mediated control of vascular function: Perspectives to pharmacological approaches in controlling vascular complications;Rolle des Renin - Angiotensin Systemes bei der Regulation der Gefäßfunktion: Perspektiven pharmakologischer Ansätze zur Kontrolle von vaskulären Komplikationen

Vasa - European Journal of Vascular Medicine

Volumn 43, Issue 6, 2014, Pages 404-414

  Pernomian, Laena ^a   Pernomian, Larissa ^a   Restini, Carolina Baraldi Araújo ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF RIBEIRÃO PRETO   (Brazil)

Author keywords

Angiotensin II; Angiotensin (1 7); AT1 receptors; Mas receptors; Reactive oxygen species; Vascular dysfunction

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4, 5, 6, 7 TETRAHYDRO 1H IMIDAZO [4, 5 C] PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN [1-7]; ARGIPRESSIN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LISINOPRIL; LOSARTAN; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PHENYLEPHRINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C; PROTEIN TYROSINE PHOSPHATASE SHP 1; RAC PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SUPEROXIDE; SUPEROXIDE DISMUTASE; TELMISARTAN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN I (1-7); DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; G PROTEIN COUPLED RECEPTOR; ONCOPROTEIN; PEPTIDE FRAGMENT; PROTO-ONCOGENE PROTEINS C-MAS-1;

AGING; ATHEROSCLEROSIS; BLOOD VESSEL TONE; DIABETES MELLITUS; ENZYME ACTIVATION; HUMAN; HYPERTENSION; INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR DISEASE; VASOCONSTRICTION; VASODILATATION; ANIMAL; BLOOD VESSEL; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; VASCULAR DISEASES;

ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD VESSELS; HUMANS; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; PROTO-ONCOGENE PROTEINS; REACTIVE OXYGEN SPECIES; RECEPTORS, G-PROTEIN-COUPLED; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION; VASCULAR DISEASES;

EID: 84925222353     PISSN: 03011526     EISSN: 16642872     Source Type: Journal    
DOI: 10.1024/0301-1526/a000387     Document Type: Review

References (75)

1. Herichova I, Szantoova K. Reninan-giotensin system: upgrade of recent knowledge and perspectives. Endocrine Regulations. 2014; 47: 39–52.
2. Guimarães PB, Alvarenga EC, Si-queira PD et al. Angiotensin II binding to angiotensin I-converting enzyme triggers calcium signaling. Hypertension. 2011; 57: 965–72.
3. Lavoie J, Sigmund CD. Minireview: Overview of the renin-angiotensin system - an endocrine and paracrine system. Endocrinology. 2003; 144: 2179–83.
4. Calò LA, Schiavo S, Davis PA, Pagnin E, Mormino P, D’Angelo A, Pessina AC Angiotensin II signaling via type 2 receptors in a human model of vascular hyporeactivity: implications for hypertension. J Hy-pertens. 2010; 28: 111–8.
5. Schinzari F, Tesauro M, Rovella V, Adamo A, Mores N, Cardillo C. Coexistence of functional angiotensin II type 2 receptors mediating both vasoconstriction and vasodilation in humans. J Hypertension. 2011; 29: 1743–48.
6. Donato V, Lacquaniti A, Cernaro V, Lorenzano G, Trimboli D, Buemi A, Lupica R, Buemi M. From Water to Aquaretics: a Legendary Route. Cell Physiol Biochem. 2014; 33: 1369–88.
7. Wakui H, Dejima T, Tamura K, Un-eda K, Azuma K, Maeda A, Ohsawa M, Kanaoka T, Azushima K, Ko-bayashi R, Matsuda M, Yamashita A, Umemura S. Activation of angiotensin II type 1 receptor-associated protein exerts an inhibitory effect on vascular hypertrophy and oxidative stress in angiotensin II-mediated hypertension. Cardiovasc Res. 2013; 100: 511–9.
8. Pernomian L, Gomes MS, Restini CBA, Ramalho LNZ, Tirapelli CR, Oliveira AM. The role of reactive oxygen species in the modulation of the contraction induced by angiotensin II in carotid artery from diabetic rat. European Journal of Pharmacology. 2012; 678: 15–25.
9. Patel K P, Mayhan WG, Bidasee KR, Zheng H. Enhanced angiotensin II-mediated central sympathoex-citation in streptozotocin-induced diabetes: role of superoxide anion. Am J Physiol Regul Integr Comp Physiol. 2011; 300: 311–20.
10. Shestakova M V. Renin-angiotensin-aldosteron system: evolution of views from renin discovery to nowadays. Perspectives of therapeutic block. Ter Arkh 2011; 71–7.
11. Reis WL, Saad WA, Camargo LA, Elias LLK, Rodrigues JA. Central nitrergic system regulation of neu-roendocrine secretion, fluid intake and blood pressure induced by an-giotensin-II. Behavioral and Brain Functions. 2010; 6: 64–72.
12. Zhou Y, Dirksen WP, Babu GJ, Periasamy M. Differential vasocon-strictions induced by angiotensin II: role of AT1 and AT2 receptors in isolated C57BL/6J mouse blood vessels. Am J Physiol Heart Circ Physiol. 2003; 285: 2797–803.
13. Fernandes L, Loiola RA, Tostes RCA, Nigro D, Fortes ZB, Carva-lho MHC. Angiotensin II-induced venoconstriction involves both AT1 and AT2 receptors and is counterbalanced by nitric oxide. Peptides. 2005; 26: 2458–63.
14. Durand MJ, Phillips SA, Widlansky ME, Otterson MF and Gutterman DD. The Vascular Renin Angiotensin System Contributes to Blunted Vasodilation Induced by Transient High Pressure in Human Adipose Microvessels. Am J Physiol Heart Circ Physiol. 2014, article in press (doi:10.1152/ajpheart.00055.2014).
15. Shan H, Zhang S, Li X, Yu K, Zhao X, Chen X, Jin B, Bai X. Valsartan ameliorates ageing-induced aorta degeneration via angiotensin II Type 1 receptor-mediated ERK activity. J Cell Mol Med. 2014; 20: 1–10.
16. San Martin A, Griendling KK. NADPH oxidases: progress and opportunities. Antioxid Redox Signal. 2014; 20: 2692–4.
17. Zhang H, Schmeisser A, Garlichs CD et al. Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH-/ NADPH-oxidases. Cardiovasc Res. 1999; 44: 215–22.
18. Galougahi KK, Liu CC, Gentile C, Kok C, Nunez A, Garcia A, Fry NAS, Davies MJ, Hawkins CL, Rasmussen HH, Figtree GA. Glutathionylation mediates angiotensin II-induced eNOS uncoupling, amplifying NA-DPH oxidase-dependent endothe-lial dysfunction. J Am Heart Assoc. 2014; 3: e000731.
19. Jin L, Ying Z, Hilgers RHP et al. Increased RhoA/Rho-kinase signaling mediates spontaneous tone in aorta from angiotensin II-induced hypertensive rats. The Journal of Pharmacology and Experimental T erapeutics. 2006; 318: 288–95.
20. Wong MS, Vanhoutte PM. COX-mediated endothelium-dependent contractions: from the past to recent discoveries. Acta Pharmacol Sin. 2010; 31: 1095–1102.
21. Cai AND, Montezano AC, Burger D, Touyz RM. Angiotensin II, NADPH Oxidase, and redox signaling in the vasculature. Antioxid. Redox Signal. 2012, 19(10): 1110–20.
22. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling KK. Angiotensin II stimulation of NAD(P)H oxidase activity–upstream Mediators. Circ Res. 2002; 91: 406–13.
23. Jackson EK, Gillespie DG, Zhu C, Ren J, Zacharia LC, Mi Z. Alpha2-adrenoceptors enhance angioten-sin II-induced renal vasoconstric-tion: role for NADPH oxidase and RhoA. Hypertension. 2008; 51(3): 719–26.
24. Cui TX, Nakagami H, Iwai M, Take-da Y, Shiuchi T, Daviet L, Nahmias C, Horiuchi M. Pivotal role of ty-rosine phosphatase SHP-1 in AT2 receptor-mediated apoptosis in rat fetal vascular smooth muscle cell. Cardiovascular Research. 2001; 49: 863–71.
25. Tea BS, Sarkissian SD, Touyz RM, Hamet P, deBlois D. Proapoptotic and growth-inhibitory role of an-giotensin II type 2 receptor in vascular smooth muscle cells of spontaneously hypertensive rats in vivo. Hypertension. 2000; 35:1069–73.
26. Sohn HY, Raf U, Hoffmann A, Gloe T, Heermeier K, Galle J, Pohl U. Differential role of angiotensin II receptor subtypes on endothelial superoxide formation. British Journal of Pharmacology. 2000; 131: 667–72.
27. Alvarez SE, Seguin LR, Villarreal RS, Nahmias C, Ciuffo GM. Involvement of c-Src tyrosine kinase in SHP-1 phosphatase activation by Ang II AT2 receptors in rat fetal tissues. Journal of Cellular Biochemistry. 2008; 105: 703–11.
28. Touyz RM, Cruzado M, Tabet F, Yao G, Salomon S, Schiffrin EL. Redox-dependent MAP kinase signaling by Ang II in vascular smooth muscle cells: role of receptor tyrosine kinase transactivation. Can J Physiol Pharmacol. 2003; 81: 159–67.
29. Silva BR, Pernomian L, Grando MD, Amaral JH, Tanus-Santos JE, Bendhack LM. Hydrogen peroxide modulates phenylephrine-induced contractile response in renal hypertensive rat aorta. European Journal of Pharmacology. 2013; 721: 193–200.
30. Nishi EE, Bergamaschi CT, Oliveira-sales EB, Simon KA, Campos RR. Losartan reduces oxidative stress within the rostral ventrolateral medulla of rats with renovascular hypertension. American Journal of Hypertension. 2013; 26: 858–65.
31. Takahashi M, Suzuki E, Takeda R et al. Angiotensin II and tumor necrosis factor-α synergistically promote monocyte chemoattrac-tant protein-1 expression: roles of NF-κB, p38, and reactive oxygen species. Am J Physiol Heart Circ Physiol. 2008, 294: 2879–88.
32. Chen XL, Zhang Q, Zhao R, Medford RM. Superoxide, H2O2, and iron are required for TNF-α-induced MCP-1 gene expression in endothelial cells: role of Rac1 and NADPH oxidase. Am J Physiol Heart Circ Physiol. 2004; 286: 1001–07.
33. Schmeisser A, Soehnlein O, Illmer T et al. ACE inhibition lowers an-giotensin II-induced chemokine expression by reduction of NF-kappa B activity and AT1 receptor expression. Biochem Biophys Res Com-mun.2004; 325: 532–40.
34. Strawn WB, Chappell MC, Dean RH, Kivlighn S, Ferrario CM. Inhibition of early atherogenesis by losartan in monkeys with diet induced hypercholesterolemia. Circulation. 2000; 101: 1586–93.
35. Hayek T, Attias J, Coleman R et al. The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E-deficient mice. Cardiovasc Res. 1999; 44: 579–87.
36. Takai S, Kim S, Sakonjo H, Miyazaki M. Mechanisms of angiotensin II type 1 receptor blocker for anti-atherosclerotic effect in monkeys fed a high-cholesterol diet. J Hypertens. 2003; 21: 361–69.
37. Takaya T, Kawashima S, Shinohara M et al. Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. Atherosclerosis. 2006; 186: 402–10.
38. Chin LC, Achike FI, Mustafa MR. Hydrogen peroxide modulates an-giotensin II-induced contraction of mesenteric arteries from strep-tozotocin-induced diabetic rats. Vascular Pharmacology. 2007; 46: 223–28.
39. Saini AK, Patel RJ, Sharmac SS, HS AK. Edaravone attenuates hydroxyl radical stress and augmented angio-tensin II response in diabetic rats. Pharmacol Res. 2006; 54: 6–10.
40. Matsumoto S, Shimabukuro M, Fukuda D et al. Azilsartan, an an-giotensin II type 1 receptor blocker, restores endothelial function by reducing vascular inf ammation and by increasing the phosphorylation ratio Ser1177/T r497 of endotheli-al nitric oxide synthase in diabetic mice. Cardiovascular Diabetology. 2014; 13: 30 (1–10).
41. Donoghue M, Hsieh F, Baronas E et al. A novel angiotensin-converting enzyme-related carboxypepti-dase (ACE2) converts angiotensin I to angiotensin 1–9. Circ Res. 2000; 87: 1–9.
42. Kohara K, Brosnihan KB, Chappell MC, Khosla MC, Ferrario CM. Angiotensin-(1–7). A member of circulating angiotensin peptides. Hypertension. 1991; 17: 131–8.
43. Santos RAS, Simoes e Silva AC, Maric C et al. Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA. 2003; 100: 8258–63.
44. Iizuka K, Kusunoki A, Machida T, Hirafugi M. Angiotensin II reduces membranous angiotensin-convert-ing enzyme 2 in pressurized human aortic endothelial cells. J Renin An-giotensin Aldosterone Syst. 2009; 10: 210–5.
45. Igase M, Strawn WB, Gallagher PE, Geary RL, Ferrario CM. Angioten-sin II AT1 receptors regulate ACE2 and angiotensin-(1–7) expression in the aorta of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2005; 289: 1013–9.
46. Lavrentyev EN, Malik KU. High glucose-induced Nox1-derived superoxides downregulate PKC-βII, which subsequently decreases ACE2 expression and ANG(1–7) formation in rat VSMCs. Am J Physiol Heart Circ Physiol. 2009; 296: 106–18.
47. Rentzch B, Todiras M, Iliescu R et al. Transgenic angiotensin-converting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function. Hypertension. 2008; 52: 967–73.
48. Vickers C, Hales P, Kaushik V et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002; 277: 14838–43.
49. Meng W, Busija DW. Comparative effects of angiotensin-(1–7) and an-giotensin II on piglet pial arterioles. Stroke. 1993; 24: 2041–44.
50. Brosnihan KB, Li P, Ferrario CM. Angiotensin-(1–7) dilates canine coronary arteries through ki-nins and nitric oxide. Hyperten-sion.1996; 27: 523–28.
51. Zhi J-M, Chen R-F, Wang J, Jiao X-Y, Zhao R-R. Comparative studies of vasodilating effects of angioten-sin-(1–7) on the dif erent vessels. Acta Physiol Sin. 2004; 56: 730–4.
52. Tirapelli CR, Fukada SY, de Godoy MAF, de Oliveira AM. Analysis of the mechanisms underlying the va-sorelaxant action of angiotensin II in the isolated rat carotid. Life Sci. 2006; 78: 2676–82.
53. Jaiswal N, Diz DI, Chappell MC, Khosla MC, Ferrario CM. Stimulation of endothelial cell prostaglan-din production by angiotensin pep-tides. Characterization of receptors. Hypertension. 1992; 19 (2 Suppl): II49–55.
54. Mutahalif MM, Benter IF, Uddin MR, Harper JL, Malik KU. Signal transduction mechanisms involved in angiotensin-(1–7)-stimulated arachidonic acid release and pros-tanoid synthesis in rabbit aortic smooth muscle cells. J Pharmaco-lExpT er. 1998; 284: 388–98.
55. Sampaio WO, Santos RAS, Faria-Silva R, Machado LTM, Schif rin EL, Touyz RM. Angiotensin-(1–7) through receptor masmediates en-dothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension. 2007; 49: 185–92.
56. Heitsch H, Brovkovych S, Malinski T, Wiemer G. Angiotensin-(1–7)-stim-ulated nitric oxide and superoxide release from endothelial cells. Hypertension. 2001; 37: 72–76.
57. Wiemer G, Dobrucki LW, Louka FR, Malinski T, Heitsch H. AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1–7) on the endotheli-um. Hypertension. 2002; 40: 847–52.
58. Polizio AH, Gironacci MM, Toma-ro ML, Peña C. Angiotenin-(1–7) blocks the angiotensin II-stimulated superoxide production. Pharmacol Res. 2007; 56: 86–90.
59. Sampaio WO, de Castro CH, Santos RAS, Schif rin EL, Touyz RM. An-giotensin-(1–7) counterregulates angiotensin II signaling in human endothelial cells. Hypertension. 2007; 50: 1093–98.
60. Xu P, Costa-Gonçalves AC, Todi-ras M et al. Endothelial dysfunction and elevated blood pressure in mas gene-deleted mice. Hypertension. 2008; 51 [part 2]: 547–80.
61. Rabelo LA, Xu P, Todiras M et al. Ablation of angiotensin (1–7) receptor Mas in C57Bl/6 mice causes endothelial dysfunction. Journal of the American Society of Hypertension. 2008; 2: 418–24.
62. Ohshima K, Mogi M, Nakaoka H, Iwanami J, Min LJ, Kanno H, Tsuku-da K, Chisaka T, Bai HY, Wang XL, Ogimoto A, Higaki J, Horiuchi M. Possible role of angiotensin-con-verting enzyme 2 and activation of angiotensin II type 2 receptor by an-giotensin-(1–7) in improvement of vascular remodeling by angiotensin II type 1 receptor blockade. Hypertension. 2014; 63: 53–59.
63. Lovren F, Pan Y, Quan A et al. An-giotensin converting enzyme-2 confers endothelia protection and attenuates atherosclerosis. Am J Physiol Heart Circ Physiol. 2008; 295: 1377–84.
64. Benter IF, Yousif MHM, Dhaunsi GS, Kaur J, Chappell MC, Diz DI. Angiotensin-(1–7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats. Am J Nephrol. 2008; 28: 25–33.
65. Wong TP, Ho KY, Ng EK, Deb-nam ES, Leung PS. Upregulation of ACE2-ANG-(1–7)-Mas axis in jejunal enterocytes of type 1 diabetic rats: implications for glucose transport. Am J Physiol Endocrinol Metab. 2012; 303: 669–81.
66. Durand MJ, Raf ai G, Weinberg BD, Lombard JH. Angiotensin-(1–7) and low-dose angiotensin II infusion reverse salt-induced endo-thelial dysfunction via dif erent mechanisms in rat middle cerebral arteries. Am J Physiol Heart Circ Physiol. 2010; 299: 1024–33.
67. Tesanovic S, Vinh A, Gaspari TA, Casley D, Widdop RE. Vasoprotec-tive and atheroprotective effects of angiotensin (1–7) in apolipo-protein E-deficient mice. Arterio-scler Thromb Vasc Biol. 2010; 30: 1606–13.
68. Stegbauer J, Potthof SA, Quack I et al. Chronic treatment with an-giotensin-(1–7) improves renal endothelial dysfunction in apo-lipoprotein E-deficient mice. Br J Pharmacol. 2011; 163: 974–83.
69. Wassmann S, Hilgers S, Laufs U et al. Angiotensin II type 1 receptor antagonism improves hypercho-lesterolemia-associated endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2002; 22: 1208–12.
70. Wong WT, Tian XY, Xu A et al. Angiotensin II type 1 receptor-dependent oxidative stress mediates endothelial dysfunction in type 2 diabetic mice. Antioxid Redox Signal. 2010; 13: 757–68.
71. Tiyerili V, Becher UM, Aksoy A et al. AT1-receptor-deficiency induced atheroprotection in diabetic mice is partially mediated via PPARγ. Cardiovasc Diabetol. 2012; 12: 30–8.
72. Xia H, Feng Y, Obr TD et al. Angio-tensin II type 1 receptor-mediated reduction of angiotensin-converting enzyme 2 activity in the brain impairs baroref ex function in hypertensive mice. Hypertension. 2009; 53: 210–6.
73. Deddish PA, Marcic B, Jack-man HL et al. N-domain specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotensin-(1–7) and keto-ACE. Hypertension. 1998; 31: 912–7.
74. Luque M, Martim P, Martell N et al. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1–7) in essential hypertension. Journal of Hypertension. 1996; 14: 799–805.
75. Takai S, Jin D, Aritomi S et al. Powerful vascular protection by combining cilnidipine with valsartan in stroke-prone, spontaneously hypertensive rats. Hypertension Research. 2013; 36: 342–8.